+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE



Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE



Lupus 24(10): 1087-1094



The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism (VTE) in major phase III prospective, randomized controlled trials (RCTs), but the results may not be directly generalizable to patients with APS. The primary aim is to demonstrate, in patients with APS and previous VTE, with or without systemic lupus erythematosus (SLE), that the intensity of anticoagulation achieved with rivaroxaban is not inferior to that of warfarin. Secondary aims are to compare rates of recurrent thrombosis, bleeding and the quality of life in patients on rivaroxaban with those on warfarin. Rivaroxaban in antiphospholipid syndrome (RAPS) is a phase II/III prospective non-inferiority RCT in which eligible patients with APS, with or without SLE, who are on warfarin, target international normalized ratio (INR) 2.5 for previous VTE, will be randomized either to continue warfarin (standard of care) or to switch to rivaroxaban. Intensity of anticoagulation will be assessed using thrombin generation (TG) testing, with the primary outcome the percentage change in endogenous thrombin potential (ETP) from randomization to day 42. Other TG parameters, markers of in vivo coagulation activation, prothrombin fragment 1.2, thrombin antithrombin complex and D-dimer, will also be assessed. If RAPS demonstrates i) that the anticoagulant effect of rivaroxaban is not inferior to that of warfarin and ii) the absence of any adverse effects that cause concern with regard to the use of rivaroxaban, this would provide sufficient supporting evidence to make rivaroxaban a standard of care for the treatment of APS patients with previous VTE, requiring a target INR of 2.5.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058782295

Download citation: RISBibTeXText

PMID: 25940537

DOI: 10.1177/0961203315581207


Related references

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet. Haematology 3(9): E426-E436, 2018

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome. Dr. Hannah Cohen about the results of the RAPS trial (Lancet Haematol 2016; 3: e426-36). Rheumatology 56(9): E23-E23, 2017

Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 25(3): 301-306, 2016

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis 13(7): 1264-1273, 2016

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13): 1365-1371, 2018

Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clinical Rheumatology 35(3): 801-805, 2016

Rivaroxaban to treat thrombotic antiphospholipid syndrome. Lancet. Haematology 3(9): E403-E404, 2016

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. Journal of Thrombosis and Haemostasis 14(11): 2177-2186, 2016

Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban. Thrombosis Research 153: 37-39, 2017

Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: the WAPS project. Provisional Steering Committee of the Warfarin in Antiphospholipid Syndrome (WAPS) Study. Annales de Medecine Interne 147(Suppl. 1): 38-41, 1996

Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. American Journal of Medicine 131(7): 787-794.E4, 2018

Oral anticoagulation cost in primary antiphospholipid syndrome: comparison between warfarin and hypothetical rivaroxaban. Blood Coagulation and Fibrinolysis 29(1): 135-138, 2017

Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thrombosis Research 163: 6-11, 2018

Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thrombosis Research 157: 46-48, 2017

HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Seminars in Thrombosis and Hemostasis 43(6): 562-571, 2017